PMID- 23189958
OWN - NLM
STAT- MEDLINE
DCOM- 20140224
LR  - 20190116
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 54
IP  - 8
DP  - 2013 Aug
TI  - A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant 
      for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte 
      globulin.
PG  - 1713-8
LID - 10.3109/10428194.2012.753444 [doi]
AB  - We conducted a phase I/II trial to assess the efficacy of cladribine, thiotepa 
      and antithymocyte globulin as a reduced-intensity conditioning regimen for 
      refractory or high-risk hematologic malignancy. The preparative regimen consisted 
      of cladribine 5 mg/m(2)/day for 5 days, thiotepa 200 mg/m(2)/day for 3 days and 
      ATG 3 mg/kg/day (day - 5) followed by allogeneic peripheral blood stem cell 
      transplant. Twelve patients were transplanted from a human leukocyte antigen 
      (HLA) matched family member. Two patients were treated at dose level I but both 
      experienced grade IV dose limiting toxicities, and therefore the thiotepa dose 
      was reduced to 133 mg/m(2)/day (dose level II). Only two of the next six patients 
      experienced dose limiting toxicities. Median age was 46 years. At dose level II, 
      the median time to neutrophil and platelet engraftment was 17 and 20 days, 
      respectively. The incidence of acute and chronic graft-versus-host disease (GVHD) 
      was 40% and 30%, respectively. Day + 100 non-relapse mortality was 0% and at 1 
      year was 20%. Median overall survival (OS) was 42 months and 2-year OS was 70%. 
      Median progression-free survival (PFS) was 11 months and 2-year PFS was 40%. We 
      conclude that the reduced-intensity conditioning regimen of cladribine, thiotepa 
      and ATG achieved excellent donor chimerism with acceptable toxicity.
FAU - Larsen, Jeremy T
AU  - Larsen JT
AD  - Department of Medicine, Mayo Clinic, Rochester, MN, USA.
FAU - Hogan, William J
AU  - Hogan WJ
FAU - Micallef, Ivana N
AU  - Micallef IN
FAU - Dispenzieri, Angela
AU  - Dispenzieri A
FAU - Gertz, Morie A
AU  - Gertz MA
FAU - Inwards, David J
AU  - Inwards DJ
FAU - Tun, Han W
AU  - Tun HW
FAU - Roy, Vivek
AU  - Roy V
FAU - Geyer, Susan M
AU  - Geyer SM
FAU - Allred, Jacob B
AU  - Allred JB
FAU - Wu, Wenting
AU  - Wu W
FAU - Ansell, Stephen M
AU  - Ansell SM
FAU - Elliott, Michelle A
AU  - Elliott MA
FAU - Tefferi, Ayalew
AU  - Tefferi A
FAU - Porrata, Luis F
AU  - Porrata LF
FAU - Gastineau, Dennis A
AU  - Gastineau DA
FAU - Lacy, Martha Q
AU  - Lacy MQ
FAU - Litzow, Mark R
AU  - Litzow MR
LA  - eng
PT  - Clinical Trial, Phase I
PT  - Clinical Trial, Phase II
PT  - Journal Article
DEP - 20121231
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Antilymphocyte Serum)
RN  - 47M74X9YT5 (Cladribine)
RN  - 905Z5W3GKH (Thiotepa)
SB  - IM
MH  - Adult
MH  - Antilymphocyte Serum/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - Cladribine/administration & dosage
MH  - Female
MH  - Graft Survival
MH  - Graft vs Host Disease/etiology
MH  - Hematologic Neoplasms/drug therapy/mortality/*therapy
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Thiotepa/administration & dosage
MH  - *Transplantation Conditioning
MH  - Transplantation, Homologous
MH  - Treatment Outcome
EDAT- 2012/11/30 06:00
MHDA- 2014/02/25 06:00
CRDT- 2012/11/30 06:00
PHST- 2012/11/30 06:00 [entrez]
PHST- 2012/11/30 06:00 [pubmed]
PHST- 2014/02/25 06:00 [medline]
AID - 10.3109/10428194.2012.753444 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2013 Aug;54(8):1713-8. doi: 10.3109/10428194.2012.753444. Epub 
      2012 Dec 31.